RenovoRx, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNXT research report →
Companyrenovorx.com
RenovoRx, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
- CEO
- Shaun R. Bagai
- IPO
- 2021
- Employees
- 10
- HQ
- Mountain View, CA, US
Price Chart
Valuation
- Market Cap
- $30.16M
- P/E
- -2.51
- P/S
- 20.25
- P/B
- 2.74
- EV/EBITDA
- -1.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.71%
- Op Margin
- -864.34%
- Net Margin
- -823.98%
- ROE
- -138.61%
- ROIC
- -106.86%
Growth & Income
- Revenue
- $1.12M · 2511.63%
- Net Income
- $-11,168,000 · -26.71%
- EPS
- $-0.32 · 13.51%
- Op Income
- $-12,510,000
- FCF YoY
- -20.12%
Performance & Tape
- 52W High
- $1.45
- 52W Low
- $0.70
- 50D MA
- $0.94
- 200D MA
- $1.00
- Beta
- 1.00
- Avg Volume
- 360.30K
Get TickerSpark's AI analysis on RNXT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 3, 26 | Bagai Shaun | other | 946,107 |
| Apr 3, 26 | VOLL MARK | other | 80,000 |
| Apr 3, 26 | Gentry Leesa | other | 128,550 |
| Apr 3, 26 | Agah Ramtin | other | 621,727 |
| Mar 25, 26 | VOLL MARK | other | 12,380 |
| Mar 20, 26 | Marton Laurence | buy | 9,720 |
| Mar 20, 26 | Marton Laurence | buy | 4,860 |
| Mar 20, 26 | Bagai Shaun | buy | 24,300 |
| Mar 20, 26 | Bagai Shaun | buy | 12,150 |
| Mar 20, 26 | VOLL MARK | buy | 97,200 |
Our RNXT Coverage
We haven't published any research on RNXT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RNXT Report →